During the past decade, ICS ARENSIA Exploratory Medicine conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "ICS ARENSIA Exploratory Medicine" are "Ulcerative Colitis" (2 trials), "Crohn's Disease" (1 trials) and "Systemic Lupus Erythematosus" (1 trials). Many other conditions were trialed in "ICS ARENSIA Exploratory Medicine" in a lesser frequency.

Most popular intervention types in "ICS ARENSIA Exploratory Medicine" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "UTTR1147A" (2 trials), "Mosunetuzumab" (1 trials), "Tocilizumab" (1 trials), "UTTR1147A Placebo" (1 trials) and "Vedolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "ICS ARENSIA Exploratory Medicine" are 3 trials for "All" genders.

Currently, there are NaN active trials in "ICS ARENSIA Exploratory Medicine". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in ICS ARENSIA Exploratory Medicine, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ICS ARENSIA Exploratory Medicine, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".